New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy

Molecular Pharmacology

Volumn 57, Issue 4, 2000, Pages 679-686

  Rousselle, Christophe ^a   Clair, Philippe ^b   Lefauconnier, Jeanne Marie ^a   Kaczorek, Michel ^b   Scherrmann, Jean Michel ^a   Temsamani, Jamal ^b  

^a HÔPITAL FERNAND WIDAL   (France)

^b Synt:em   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PEPTIDE;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; DRUG BRAIN LEVEL; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034126420     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.57.4.679     Document Type: Article

References (42)

1. Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, Mori T, Hori S, Kohno K and Kuwano M (1994) Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int J Cancer 58:860-864.
2. Atherton E and Sheppard RC (1989) Solid Phase Peptide Synthesis: A Practical Approach. IRL Press at Oxford University Press, Oxford, England.
3. Aumelas A, Mangoni M, Roumestand C, Chiche L, Despaux E, Grassy G, Calas B and Chavanieu A (1996) Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem 237:575-583.
4. Benrabh H and Lefauconnier JM (1996) Blood-endothelial cell and blood-brain transport of L-proline, alpha-aminoisobutyric acid, and L-alanine. Neurochem Res 21:1227-1235.
5. Blasberg RG and Groothuis DR (1986) Chemotherapy of brain tumors: Physiological and pharmacokinetic considerations. Semin Oncol 13:70-82.
6. Bummer PM, Aziz S and Gillepsie MN (1995) Inhibition of pulmonary surfactant biophysical activity by cationic polyamino acids. Pharm Res 12:1658-1663.
7. Celio LA, Digregorio GJ, Ruch E, Pace JN and Piraino AJ (1982) Doxorubicin concentrations in rat plasma, parotid saliva, and bile and protein binding in rat plasma. Arch Int Pharmacodyn Ther 260:180-188.
8. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E and Kim S (1993) Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 50:261-264.
9. Colombo T, Zucchetti M and D'Incalci M (1994) Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 269:22-27.
10. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
11. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G and Prochiantz A (1996) Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271:18188-18193.
12. Derossi D, Chassaing G and Prochiantz A (1998) Trojan peptides: The penetratin system for intracellular delivery. Trends Cell Biol 8:84-87.
13. Derossi D, Joliot AH, Chassaing G and Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444-10450.
14. Drion N, Lemaire M, Lefauconnier JM and Scherrmann JM (1996) Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem 67:1688-1693.
15. Ford JM and Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199.
16. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Anna Rev Biochem 62:385-427.
17. Harwig SS, Swiderek KM, Lee TD and Lehrer RI (1995) Determination of disulphide bridges in PG-2, an antimicrobial peptide from porcine leukocytes. J Peptide Sci 1:207-215.
18. Hughes CS, Vaden SL, Manaugh CA, Price GS and Hudson LC (1998) Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J Neurooncol 37:45-54.
19. Huwyler J, Wu D and Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169.
20. Joliot A, Maizel A, Rosenberg D, Trembleau A, Dupas S, Volovitch M and Prochiantz A (1998) Identification of a signal sequence necessary for the unconventional secretion of Engrailed homeoprotein. Curr Biol 8:856-863.
21. Joliot A, Trembleau A, Raposo G, Calvet S, Volovitch M and Prochiantz A (1997) Association of Engrailed homeoproteins with vesicles presenting caveolae-like properties. Development 124:1865-1875.
22. Jolliet-Riant P and Tillement JP (1999) Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol 13:16-26.
23. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
24. Klopman G, Shi LM and Ramu A (1997) Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 52:323-334.
25. Krishna R, De Jong G and Mayer LD (1997) Pulse exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. Anticancer Res 17:3329-3334.
26. Kroll RA and Neuwelt EA (1998) Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 42:1083-1099.
27. Lefrak EA, Pitha J, Rosenheim S and Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314.
28. Malhotra BK, Lemaire M and Sawchuk J (1994) Investigation of the distribution of eab 515 to cortical ECF and CSF in freely moving rats utilizing microdialysis. Pharmacol Res 11:1223-1232.
29. Mangoni ME, Aumelas A, Charnet P, Roumestand C, Chiche L, Despaux E, Grassy G, Calas B and Chavanieu A (1996) Change in membrane permeability induced by protegrin 1: Implication of disulphide bridges for pore formation. FEBS Lett 383:93-98.
30. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M and Garnier-Suillerot A (1996) Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharmacol 49:532-539.
31. Mayer LD (1998) Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies. Cancer Metastasis Rev 17:211-218.
32. Ohnishi T, Tamai I, Sakanaka K, Sakata A, Yamashima T, Yamashita J and Tsuji A (1995) In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol 49:1541-1544.
33. Pardridge WM (1997) Drug delivery to the brain. J Cereb Blood Flow Metab 17:713-731.
34. Pardridge WM and Landaw EM (1984) Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. Empiric testing of the free hormone hypothesis. J Clin Invest 74:745-752.
35. Rousselle CH, Lefauconnier JM and Allen DD (1998) Evaluation of anesthetic effects on parameters for the in situ rat brain perfusion technique. Neurosci Lett 257: 139-142.
36. Schroeder U, Sommerfeld P, Ulrich S and Säbel BA (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharmacol Sci 87:1305-1307.
37. Schwarze SR, Ho A, Vocero-Akbani A and Dowdy SF (1999) In vivo protein transduction: Delivery of a biologically active protein into mouse. Science (Wash DC) 285:1569-1572.
38. Smith QR (1996) Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm Biotechnol 8:285-307.
39. Takasato Y, Rapoport SI and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493.
40. Triguero D, Buciak J and Pardridge WM (1990) Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 54:1882-1888.
41. Tsuji A (1998) P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit 20:588-590.
42. Van Asperen J, Van Tellingen O, Tijssen F, Schinkel AH and Beijnen JH (1999) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79:108-113.